Alzheimer’s Disease
- Revised criteria for diagnosis and staging of Alzheimer’s disease: Alzheimer’s Association Workgroup
- Alzheimer’s Disease Facts and Figures 2024
- Focusing on earlier diagnosis of Alzheimer’s disease
- For Patients: Treatments for Alzheimer’s
- Alzheimer’s Disease: Key Insights from Two Decades of Clinical Trial Failures
- Alzheimer’s disease drug development pipeline
- Treatment with GLP-1 RAs and incidence of dementia
- Donanemab in Early Symptomatic Alzheimer Disease
- Alzforum: news and information dedicated to Alzheimer’s disease
Amyotrophic Lateral Sclerosis
Migraine
- The American Headache Society Consensus Statement: Update on Integrating New Migraine Treatments into Clinical Practice
- Prevention of Episodic Migraine Headache Using Pharmacologic Treatments in Outpatient Settings: A Clinical Guideline From the American College of Physicians
- Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders (ICHD), 3rd edition
- Gepants in Primary Care: A Targeted Approach to Acute and Preventive Treatment of Migraine
- Setting higher standards for migraine prevention: A position statement of the International Headache Society
- CGRP Therapies are a First-Line Option for the Prevention of Migraine: An American Headache Society Position Statement Update
- Rimegepant, an Oral Calcitonin Gene-Related Peptide Receptor Antagonist, for Migraine
- Atogepant for the Preventive Treatment of Chronic Migraine (PROGRESS): A Phase 3 Trial
- Atogepant for the Prevention of Episodic Migraine in Adults: A Phase 2b/3 Trial
- Time Course of Efficacy of Atogepant for the Preventive Treatment of Migraine: The ADVANCE Trial
- Long-term Safety, Efficacy and Functional Outcomes of Atogepant for the Preventive Treatment of Migraine
- Safety and Efficacy of Atogepant for the Preventive Treatment of Episodic Migraine in Adults for Whom Conventional Oral Preventive Treatments Have Failed (ELEVATE): A Phase 3b Trial
- Efficacy, Safety, and Tolerability of Rimegepant Orally Disintegrating Tablet for the Acute Treatment of Migraine: A Phase 3 Trial
- Oral Rimegepant for Preventive Treatment of Migraine: A phase 2/3 Trial
- Efficacy and Safety of Rimegepant for the Preventive Treatment of Migraine in Japan
- Effects of Rimegepant 75 mg on Monthly Migraine Days: A 52-Week, Open-Label Extension Study
- A 52-week Open-Label Extension Study to Evaluate the Safety and Efficacy of Oral Rimegepant for the Preventive Treatment of Migraine
- Monthly Migraine Days, Tablet Utilization, and Quality of Life Associated with Rimegepant: Post Hoc Results from an Open Label Safety Study
- Clinician-Patient Dialogue About Preventive Chronic Migraine Treatment
- Ubrogepant, an Acute Treatment for Migraine, Improved Patient-Reported Functional Disability and Satisfaction in 2 Single-Attack Phase 3 Randomized Trials, ACHIEVE I and II
- Efficacy of Ubrogepant in the Acute Treatment of Migraine With Mild Pain vs Moderate or Severe Pain
- Real-world Effectiveness, Satisfaction, and Optimization of Ubrogepant for the Acute Treatment of Migraine in Combination with OnabotulinumtoxinA: The COURAGE Study
- Reduction of Pain and Functional Disability Over Time in Patients Treated with Zavegepant: A Post-Hoc Analysis
- Safety, Tolerability, and Efficacy of Zavegepant 10 mg Nasal Spray for the Acute Treatment of Migraine: A Phase 3 Trial
- Efficacy and Safety of Intranasal Agents for the Acute Treatment of Migraine: A Systematic Review and Network Meta-Analysis
- Diagnosis and Management of Migraine in Ten Steps
- Pathophysiology of Migraine: A Disorder of Sensory Processing
- Migraine Burden of Disease: From the Patient’s Experience to a Socio-Economic View
- Efficacy and Safety of Erenumab for Nonopioid Medication Overuse Headache in Chronic Migraine: A Phase 4 Trial
- Efficacy and Safety of Erenumab in Adults With Medication Overuse Headache: Final Results From a Phase 4 Trial
- CGRP-Targeted Migraine Therapies in Patients With Vascular Risk Factors or Stroke: A Review
- Prevalence and Burden of Migraine in the United States: A Systematic Review
- Red and Orange Flags for Secondary Headaches in Clinical Practice: SNNOOP10 List
- Frequently Asked Questions About Migraine Symptoms
- Atogepant for the Preventive Treatment of Migraine
Multiple Sclerosis (MS)
- Clinician Pocket Guide: What to Screen For and What to Follow When Using Disease-Modifying Therapies (DMTs)
- MS, COVID-19 and vaccines – updated global advice
- Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper)
- Aging and efficacy of disease-modifyingtherapies in multiple sclerosis: a meta-analysis of clinical trials
- Monitoring of safety and effectiveness of cladribine in multiple sclerosis patients over 50 years
- BEACON: BEtaferon prospective study on Adherence, COping and Nurse support): Clinical characteristics of middle-aged and older patients with MS treated with interferon beta-1b
- Guidelines of the Consortium of MS Centers MRI Protocol for the Diagnosis and Follow-up of MS
- Adherence — Patient Information
- Resources for You and Your Practice
- Mobile Applications for People with Multiple Sclerosis (MS)
- Family Planning and Pregnancy With Multiple Sclerosis
- Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis
- Disease-modifying Therapies for MS
Myasthenia Gravis
- International Consensus Guidance for Management of Myasthenia Gravis
- International Consensus Guidance for Management of Myasthenia Gravis – 2020 Update
- Myasthenia Gravis Foundation of America
- NIH – Myasthenia Gravis
- Treatment options for myasthenia gravis
- New and Emerging Biological Therapies for Myasthenia Gravis: A Focussed Review for Clinical Decision-Making
- Myasthenia gravis: the future is here
- New and emerging treatments for myasthenia gravis
- Safety and efficacy of nipocalimab in adults with generalised myasthenia gravis (Vivacity-MG3): a phase 3, randomised, double-blind, placebo-controlled study
- The efficacy and safety of FcRn inhibitors in patients with myasthenia gravis: a systematic review and meta-analysis
- Measuring Clinical Treatment Response in Myasthenia Gravis
Parkinson’s Disease
Stroke
- Impact of Echocardiographic Parameters on Recurrent Stroke in the Randomized REDUCE PFO Cryptogenic Stroke Trial
- Heterogeneity of Treatment Effects in an Analysis of Pooled Individual Patient Data From Randomized Trials of Device Closure of Patent Foramen Ovale After Stroke
- Etiologic Workup in Cases of Cryptogenic Stroke: A Systematic Review of International Clinical Practice Guidelines
- Inclusion and Exclusion Criteria for Intravenous Alteplase in Acute Ischemic Stroke
- Signs and Symptoms of a Stroke
- Recognize Warning Signs of a Stroke (Act FAST)
- Proposal for Updated Nomenclature and Classification of Potential Causative Mechanism in Patent Foramen Ovale-Associated Stroke
- American Academy of Neurology practice advisory update: Patent foramen ovale and secondary stroke prevention
- REDUCE trial: Five-Year Outcomes of PFO Closure or Antiplatelet Therapy for Cryptogenic Stroke
